For home cooks like me, I recommend CBD extra virgin olive oil because of its versatility. You can drizzle it on everything from salads to pizza and even brambleberry ice cream. I even make a miso-honey glaze while using a little bit of the stuff. In particular, I’m a big fan of Pot d’Huile, which was founded by San Francisco-based Yannick Crespo. It’s stellar. For one thing, it tastes exactly the way good EVOO should—with none of that “green” marijuana aftertaste. It also doesn’t remind me of Bertolli—not that there’s anything wrong with it. But you know, delicious EVOO is nothing like Bertolli. Crespo attributes Pot d’Huile’s non-compromising flavor with the ethanol extraction process that the company uses, which is slightly more expensive—in addition to using locally-sourced oil from Northern California. The flavor is so good that Pot d’Huile regularly hosts pop-up dinners with chefs who are so into it. (And if you ever find yourself in a city where they’re hosting, it’d be a shame to skip out.) But beyond all that, Pot d’Huile makes dosing easy: It’s 1mg of CBD per 1ml of olive oil. So all you’ll really need to incorporate CBD EVOO into your meals are measuring spoons. And yes, they do have THC olive oils as well—at $50 for 100ml. In the future, the company also has plans on creating a THC–CBD oil. Easy peasy.
Cheeba Chews has a major fan base partially because of its potency and consistent dosage. And for . [+] good reason. Each miniscule 1:1 chew contains 50mg of THC and 50mg of CBD. So consume it with caution.
The New York Times may have called cannabis brand, Beboe, the Hermès of cannabis. But Lord Jones’ . [+] packaging is actually reminiscent of an Hermès box.
But be wary of the products you buy and do your research. Some cannabis products work while many don’t, mainly due to lack of regulatory testing from the powers that be and quality control within companies, which is apparently common in the cannabis industry. Your best bet to avoid buying bogus products is to purchase your goods in states where cannabis is legal—because certain systems, standards, and protocols have already been put in place (such as seed-to-sale tracking).
You see, I experienced my first “episode” at 31. I was standing over the sink one fall morning and sneezed. Hard. Before I knew it, my lower back gave way. Then a tremendous pain engulfed my body. And get this: The episodes recurred whenever they felt like it—peskier than a hungry mosquito. Twice a year if I was lucky, more if I wasn’t. (Once, in Paris, I actually had to purchase a cane. The only consolation to that otherwise crippling experience was that it felt comically chic: I was hobbling in The City of Light, clad in Hermès scarves.)
Recess, a flavored sparkling water drink with hemp extract and adaptogens, has been popular among . [+] millennials. But the verdict is out on whether it’s effective or not.
These days I’m a believer. It’s difficult to ignore the fact that Epidiolex—the CBD-based epilepsy medication—was approved by the F.D.A last year. Or that athletes are abandoning NSAIDs (nonsteroidal anti-inflammatory drugs, such as ibuprofen or naproxen) for greener alternatives. Then there are Alfie Dingley and Billie Caldwell in the UK: Their cases involving rare forms of epilepsy have prompted UK home secretary Sajid Javid to say that specialists will soon be able to prescribe cannabis-based medication. Beyond that, nearly 7% of Americans are already using CBD—and given the population, that’s a staggering number.
Although a range of analytical methods have been published in recent years , there is no general agreement on which analytical method is most suitable and accurate. Additionally, there are currently no generally accepted guidelines or certifications to determine the qualifications of cannabis labs. As a result, cannabinoid analysis can differ significantly between labs , even when the exact same sample is analyzed multiple times . This not only poses a risk to consumers (who do not know how trust the label on their product) but may also lead to business-to-business conflicts about the quality or value of intermediate products. Additionally, inaccurate analytical results may lead to legal problems if the THC content of a CBD product unexpectedly turns out to be higher than the maximally allowed limit. It seems clear that a better agreement on the conditions for lab testing of cannabinoids is urgently needed.
The fact that the maximum CBD content in an oil is limited by the THC present in the herbal material used makes it attractive to add an additional amount of purified CBD to boost the percentage advertised on the label. Unfortunately, the Novel Food Catalogue of the EU states that “extracts of Cannabis sativa L. in which CBD levels are higher than the CBD levels in the plant source are novel in food” . This means that enriching a natural hemp extract with pure (often synthetic) CBD makes it a Novel Food product, with the consequence that it must undergo significant safety assessment prior to being marketed. However, it is still unclear in many EU countries if extracts with no added CBD also fall under this regime.
In just a few years, cannabidiol (CBD) has become immensely popular around the world. After initially being discovered as an effective self-medication for Dravet syndrome in children, CBD is now sold and used to treat a wide range of medical conditions and lifestyle diseases. The cannabinoid CBD, a non-psychoactive isomer of the more infamous tetrahydrocannabinol (THC), is available in a growing number of administration modes, but the most commonly known is CBD oil. There are currently dozens, if not hundreds, of producers and sellers of CBD oils active in the market, and their number is increasing rapidly. Those involved vary from individuals who prepare oils on a small scale for family and (Facebook) friends to compounding pharmacies, pharmaceutical companies, and licensed cannabis producers. Despite the growing availability of CBD, many uncertainties remain about the legality, quality, and safety of this new “miracle cure.” As a result, CBD is under scrutiny on many levels, ranging from national health organizations and agricultural lobbyists to the WHO and FDA. The central question is whether CBD is simply a food supplement, an investigational new medicine, or even a narcotic. This overview paper looks into the known risks and issues related to the composition of CBD products, and makes recommendations for better regulatory control based on accurate labeling and more scientifically supported health claims. The intention of this paper is to create a better understanding of the benefits versus the risks of the current way CBD products are produced, used, and advertised.
What Studies Tell Us
Determining risks and benefits through proper clinical trials remains highly desired, but these will take considerable time and funds. As a result, clinical data will not appear any time soon, while patients will not simply stop using the many CBD products to which they have become accustomed. Taking back regulatory control over CBD could therefore start with a more short-term and achievable approach, i.e., demanding accurate and proper labeling, reflecting in detail what each product does and does not contain, and how it was manufactured. For a clearer judgment of the potential therapeutic effects, the risks, but also the legality of a cannabis extract, it is important to know its exact composition. After all, published data from around the world has taught us that misleading labels as well as harmful contaminants are real and actual problems for CBD products. The analytical methodology and the third-party labs needed for this approach largely already exist, and could easily be optimized to quickly get a better grip on the unrestrained cannabinoid market. This approach would hold each producer strictly accountable for the quality and safety of their own products, as long as there are real legal consequences for those businesses that break the rules. Add to this a system for regular professional audits and inspections, and a crackdown on unsubstantiated health claims, and we have a reasonable system to ensure that CBD can be used responsibly by those who need it, until much needed clinical data become available.
Increasingly, CBD oil is also being promoted as a prophylactic treatment in order to prevent certain diseases from developing at all. The argument used is that the human endocannabinoid system is involved in basic life functions such as appetite, immune response, reproduction, and pain management . Because CBD functions as an indirect antagonist to human CB1 and CB2 receptors , it is reasoned that the presence of CBD prevents them from being overly activated, thereby protecting the nervous and immune systems from everyday stress. Furthermore, CBD is known to be a reasonably potent antioxidant, which further helps to protect against stressful influences . Although this clearly increases the market for CBD products, it also further erodes the scientific basis for the therapeutic use of CBD. After all, it is hard to prove scientifically that a disease was prevented by the use of a health-promoting product.
Today, CBD is used for the treatment of a wide range of medical conditions. This started with the somewhat serendipitous discovery (by parents experimenting with self-medication for their children) that CBD had a therapeutic effect on a serious form of epilepsy in children, called Dravet syndrome . This effect is now under clinical investigation with the pharmaceutical CBD product Epidiolex®, which is currently in phase 3 trials with encouraging results [9, 10]. The media attention generated by its effect on severely ill children gave CBD the push needed to become a much desired medicine almost overnight . Other medical indications that may be treated with CBD, and are supported to some extent by clinical proof, include Parkinson’s disease , schizophrenia , and anxiety disorder . However, although research into the therapeutic effects of CBD is rapidly increasing, most current uses of CBD are not (yet) supported by clinical data. The popular use of these products means that physicians may be confronted with the effects of CBD oil even when they do not prescribe it themselves.
Although contaminants come in various shapes and forms, most are relatively easy to detect, because many professional analytical labs exist that routinely screen for such contaminants in, for example, food crops, imported medicinal plants, or edible oils. The standard lab methods, as described in Pharmacopoeia monographs (e.g., USP, EP) or food regulations, could simply be applied to CBD oils, after some minor validation studies. For example, the detection of heavy metals or pesticides present in CBD oil does not significantly differ from the same analysis in, say, a shipment of olive oil. The only analysis that is not yet standard procedure in most analytical labs is the quantification of cannabinoids. Because cannabinoids are only found (with few exceptions ) in the cannabis plant, specific analytical methodology must be developed to properly determine the cannabinoid composition of the many CBD products available.